Search Results
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
rate (ORR) by RECIST 1.1 criteria, duration of response (DoR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OR) and PK analysis. About EGFRmt NSCLC Non-small cell lung
More news about: SystImmune, Inc.
Oct 16, 2025, 07:30 ET BTQ Technologies Demonstrates Quantum-Safe Bitcoin Using NIST Standardized Post-Quantum Cryptography, Protecting $2+ Trillion Market at Risk
of funds. Approximately 6.65 million Bitcoin have permanently exposed public keys, including 1.9 million BTC in early Pay-to-Public-Key (P2PK) addresses and 4 million BTC in reused addresses. These coins face "long-range attacks" where quantum computers can derive private keys offline, potentially
More news about: BTQ Technologies Corp.
Oct 15, 2025, 10:45 ET PK Companies Appoints Michael Viotto as Chief Financial Officer
underscores PK Companies' commitment to advancing its financial foundation and supporting innovation, scalability, and market leadership across all divisions; PK Industrial, PK Safety, and PK Technology & Inspection. About PK Companies
More news about: PK Companies
Oct 14, 2025, 08:06 ET TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
Primary objectives of the trial focused on safety, tolerability, pharmacokinetics ("PK") and establishment of a Phase 2 dose (RP2D). A total of sixteen patients were treated across four escalating dose levels. No significant treatment-related
More news about: TransCode Therapeutics, Inc.
Oct 13, 2025, 13:42 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Oct 13, 2025, 08:00 ET Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
residual-solvent limits; (iii) stability and delayed-release attributes (acid resistance and intestinal release); (iv) dose ranges including 1–4 mg and 8 mg; (v) PK targets such as steady-state plasma levels and exposure ranges; and (vi) a multi-step crystallization process to enrich the Z-isomer. Collectively, these
More news about: Atossa Therapeutics Inc
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Translational PK/PD modelling of LY4170156, an antibody-drug conjugate linked to exatecan via a novel cleavable polysarcosine linker
More news about: Eli Lilly and Company
Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and the secondary endpoints include DOR, DCR, PFS, OS, intracranial efficacy by RANO-BM criteria, PK and safety. About Zipalertinib Zipalertinib (development code: CLN-081/TAS6417)
More news about: Taiho Oncology
Oct 09, 2025, 07:00 ET New Clinical Data for Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy to be Presented in Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025
https://clinicaltrials.gov/ct2/show/NCT04665206) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory non-pleural and pleural malignant mesothelioma.
More news about: Vivace Therapeutics, Inc.
Oct 08, 2025, 17:44 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Oct 08, 2025, 09:00 ET Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting
The Company's presentations highlight post hoc analyses from the recently completed open-label pharmacokinetics (PK) and safety study of diazepam nasal spray for the treatment of episodes of frequent seizures in patients with epilepsy aged 2-5 years. One presentation
More news about: Neurelis, Inc.
Oct 08, 2025, 07:00 ET Vivace Therapeutics' VT3989 Granted Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04665206) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural and non-pleural malignant mesothelioma.
More news about: Vivace Therapeutics, Inc.
Oct 07, 2025, 06:00 ET InsightRX Achieves 96.1 Performance Score in KLAS Spotlight as the First Precision Dosing AI Solution
The next horizon is a future powered by InsightRX's upcoming agentic AI system. This next generation clinical decision support tool will bring together PK/PD modeling and simulation with broader sources of clinical context, including guidelines, institutional protocols, and pharmacogenomics. By collating
More news about: InsightRX
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
isolates collected at baseline from patients enrolled in the Talicia pivotal trial 8 Defined as the PK population which included those subjects in the ITT population who had demonstrated presence of any component of investigational drug at visit 3 (approx.
More news about: RedHill Biopharma Ltd.
Oct 03, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and
More news about: Celltrion
Oct 01, 2025, 07:07 ET Fall into Savings at "Autumnfest" With Natural Grocers®, Oct. 9-11, 2025
oz), Lesser Evil® Organic Popcorn (2 / $5), Amy's Kitchen® Soups (2 / $7), Nixie® Organic Sparkling Waters ($3.79 / 8 pk), Natural Grocers® Brand Bulk Organic Roasted Salted and Unsalted Pistachios ($5.49 / 10 oz) and more.[i]
More news about: Natural Grocers by Vitamin Cottage, Inc.
Sep 30, 2025, 08:00 ET AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing schedule for PVEK monotherapy and to assess the safety, tolerability, PK, immunogenicity, and antileukemia activity of PVEK when administered to subjects with CD123+ hematologic malignancies (including subjects with BPDCN,
More news about: AbbVie
Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
and Sustained Clinical Cure. In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance,
More news about: Acurx Pharmaceuticals, Inc.
Sep 29, 2025, 07:00 ET BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
30 patients with recurrent GBM. The objective of this part is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial is anticipated in H1 2027. The Phase 2a expansion part of
More news about: BioLineRx Ltd.
Sep 29, 2025, 06:35 ET Expert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in Cantanhede, Portugal.
tumors remain one of the greatest unmet needs in medicine," said Dr. Tudor Oprea, CEO of Expert Systems Inc. "By integrating predictive ADMET and PK/PD modeling with in-silico and in vitro new-approach methodologies (NAMs), we gave Mondego Bio a decisive edge — identifying high-potential PTPN2 inhibitors
More news about: Expert Systems, Inc.
Sep 29, 2025, 06:00 ET AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
activity of the heart as recorded by an electrocardiogram. Favorable pharmacokinetics (PK): PK data showed dose-proportional increases in drug exposure. ROC-101 was rapidly absorbed, and its half-life supports once-daily dosing.
More news about: AllRock Bio
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three
More news about: Pomerantz LLP
Sep 25, 2025, 20:47 ET Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
dose-escalation phase of its Phase I clinical trial, multiple confirmed partial responses (PRs) have been observed, with favorable safety and pharmacokinetic (PK) profiles consistent with expectations. Full Phase I data are expected to be released in the first half of 2026, which will mark a critical milestone
More news about: Jacobio Pharma
Sep 25, 2025, 09:00 ET Teaching Strategies Named Finalist for Three 2025 CODiE Awards
Best PK/Early Childhood Learning Solution:
More news about: Teaching Strategies